LB PHARMACEUTICALS INC

LB PHARMACEUTICALS INC is a late-stage biopharmaceutical company focused on developing new treatments for various neuropsychiatric disorders, including schizophrenia, bipolar depression, and as an add-on treatment for major depressive disorder. The company is developing a pipeline centered on its main product candidate, LB-102. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company also plans to conduct a Phase 2 clinical trial for LB-102 as an adjunctive treatment in major depressive disorder (MDD). LB-102 is a new chemical entity and a methylated version of amisulpride. Amisulpride is a second-generation antipsychotic drug approved in over 50 countries, but not in the United States, due to regulatory requirements and patent coverage issues. Amisulpride has been widely used in clinical practice since its initial approval in France in the 1980s, with at least two million monthly prescriptions in 2023 across a subset of 16 continental European countries. Data from these European prescriptions indicate that approximately 60% are for schizophrenia and schizoaffective disorders, approximately 20% for mood disorders, approximately 14% for anxiety, and the rest for other conditions. LB-102 was designed to improve upon amisulpride, aiming for a distinct therapeutic profile and strong intellectual property protection. The company believes that LB-102's mechanism of action, results from its recently completed Phase 2 trial (NOVA-1) in acute schizophrenia, and the existing clinical experience with amisulpride support its continued development for both psychosis and mood disorders.